Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Genitourinary tumours, non-prostate

3142 - Adjuvant sunitinib (SU) in patients (pts) with high risk renal cell carcinoma (RCC): Safety and therapy management in S-TRAC trial


10 Sep 2017


Genitourinary tumours, non-prostate


Cytotoxic Therapy;  Renal Cell Cancer


Michael Staehler


Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371


M. Staehler1, R.J. Motzer2, D.J. George3, H.S. Pandha4, F. Donskov5, B. Escudier6, J. Kliment7, A.J. Pantuck8, A. Patel9, L. Deannuntis10, H. Bhattacharyya11, X. Lin12, M. Lechuga13, L. Serfass14, J. Patard15, A. Ravaud16

Author affiliations

  • 1 Dept Of Urology, University of Munich, 81337 - Munich/DE
  • 2 Medical Oncology, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
  • 3 Duke Cancer Institute, Duke University Medical Center, 27710 - Durham/US
  • 4 Clinical And Experimental Medicine, University of Surrey, Surry/GB
  • 5 Oncology, Aarhus University Hospital, Aarhus/DK
  • 6 -, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 7 Urology, University Hospital, Martin/SK
  • 8 Department Of Urology, Ronald Reagan UCLA Medical Center, Los Angeles/US
  • 9 -, Spire Roding Hospital, London/GB
  • 10 -, Pfizer Inc, Collegeville/US
  • 11 -, Pfizer Inc, New York/US
  • 12 -, Pfizer Inc, La Jolla/US
  • 13 -, Pfizer S.r.L, Milan/IT
  • 14 -, Pfizer Oncology, Paris/FR
  • 15 -, Centre Hospitalier De Mont De Marsan, Mont-de-Marsan/FR
  • 16 Medical Oncology, Bordeaux University Hospital, 33000 - Bordeaux/FR


Abstract 3142


Pts with locoregional RCC at high risk (≥T3 and/or N+) of tumour recurrence post nephrectomy treated with adjuvant SU (50 mg daily; schedule 4/2) had significantly longer disease-free survival (DFS) vs. placebo (PBO; HR, 0.76; 95% CI, 0.59–0.98; P = 0.03). We report safety and therapy management data.


Reasons for SU treatment discontinuation (TDC), dose reduction (RED), dose interruption (INT), and pts TDC due to AEs by cycle, were summarized. Median time to SU TDC was calculated.


Of the 615 pts enrolled, 306 were treated with SU at a median (range) daily dose of 45.9 (8.9–52.6) mg. 71% of pts remained on SU treatment for 9 months (mo) and 56% completed the full 1-year treatment. Most common reasons for TDC were AEs (28.1%) and relapse (7.2%) in SU arm, and relapse (19.4%) and AEs (5.9%) in PBO arm. Common AEs leading to TDC, RED and INT are summarized in the Table. TDC due to AEs in cycles 1, 3, 6, and 9, respectively: 7.8%, 3.3%, 2.6%, and 1.6% in SU arm, and 0.3%, 1.3%, 0.3%, and 0% in PBO arm. In the 86 pts who DC SU, median time to TDC was 4.5 mo. Median time to first RED and INT in SU-treated pts was 2.9 and 3.0 mo, respectively. Mean change from baseline in most PRO measures including Global Health Status for SU vs PBO was not clinically meaningful (difference, -4.76; 95% CI, -6.82, -2.71). More data, including time on RED/INT, time to onset of common AEs, and the impact of AEs on pts quality of life, will be presented.Table:

855PD Most common AEs leading to TDC, dose RED and INT*

Treatment DCDose REDDose INT
Fatigue1.00.3Mucosal inflammation2.60Nausea4.91.0
Pulmonary embolism1.00.3Neutropenia2.60Diarrhoea4.61.3

Many of the AEs leading to DC and INT were grade 1/2 TDC=treatment discontinuation; RED=reduction; INT=interruption; PPE=palmar-plantar erythrodysesthesia syndrome.


No new safety signals were identified with sunitinib use in the adjuvant RCC setting. Effective therapy management, including dose RED/INT if necessary, is important as it optimizes the possibility of receiving effective treatment.

Clinical trial identification


Legal entity responsible for the study





M. Staehler: Received honoraria, consulting fees, and research grants from Pfizer, Bayer, GSK, Roche, Bristol-Myers Squib, Novartis, Exelixis and AVEO. R.J. Motzer: Received consulting fees from Pfizer, Novartis, Eisai and Exelixis. D.J. George: Received honoraria & consulting: Dendreon, Sanofi, Bayer; consulting: Medivation, Merck, Genentech, Clovis; grants: Genentech, Novartis, Janssen, Astellas, Celldex, Acerta; grants & consulting: Exelixis, Pfizer, Sanofi, Innocrin Pharma, Bristol-Myers Squib. H.S. Pandha: Received honoraria for advisory work from ipsen and Esai. F. Donskov: Received research funding from Pfizer, Novartis, and GSK. B. Escudier: Received consulting fees from Pfizer, Bristol-Myers Squib, Ipsen, ESU pharma and Novartis, and honoraria from Bayer, Roche, Pfizer, Genentech, Novartis, Bristol-Myers Squib, Eisai, Acceleron and Ipsen. A.J. Pantuck: AJ Pantuck has received consulting fees from Pfizer. L. Deannuntis, H. Bhattacharyya, X. Lin, M. Lechuga and L. Serfass: Employee of and owns stock in Pfizer. J-J. Patard: Received consulting fees from Pfizer and GSK. A. Ravaud: Member of RCC advisory boards in Pfizer, Novartis, GSK, Roche, and Bristol-Myers Squib; received institutional support grants from Pfizer and Novartis; housing and transportation for meetings and speeches by Pfizer, Novartis, Bristol-Myers Squib, Astra Zeneca and MSD. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.